Metastatic Prostate Cancer: Sorting Through the Treatment Maze – The ASCO Post

Neal Shore, MD, FACS The message still needs to get out that metastatic castration-sensitive prostate cancer should be treated with both androgen-deprivation therapy (ADT) and either docetaxel or an androgen receptor pathway inhibitor. In spite of “overwhelming” support for ADT plus abiraterone/prednisone,…

Read the full article here

Related Articles